早期子宫内膜样和浆液性子宫内膜癌前哨淋巴结超分期及隐匿转移发生率
该回顾性研究纳入2005至2018年接受原发手术分期且双侧前哨淋巴结(SLN)定位成功的临床I期子宫内膜样或浆液性子宫内膜癌患者1044例,评估超分期下孤立肿瘤细胞(ITC)、微转移和大转移及隐匿卵巢转移的发生率。结果显示低级别无肌层浸润子宫内膜样癌SLN阳性率为0,而无浸润浆液性癌中4例(10%)存在ITC或SLN阳性;隐匿卵巢转移在高危组织学类型中发生率为2-3%。
要点
- 低级别无肌层浸润子宫内膜样癌SLN阳性率为0,超分期可能不必要。
- 无浸润浆液性癌中10%(4/41)存在ITC或SLN阳性,超分期有价值。
- 隐匿卵巢转移仅见于高级别或浆液性癌,发生率为2-3%。
核心结论
- 低级别无肌层浸润子宫内膜样癌可能无需SLN超分期,而无浸润浆液性癌则有必要。
- 早期子宫内膜癌隐匿卵巢转移不常见,在高危组织学类型中发生率为2-3%。
- ITC的临床意义尚需进一步研究,尤其关于辅助治疗决策。
研究设计与样本
- 回顾性研究,纳入2005年1月至2018年12月接受原发手术分期且双侧SLN定位成功的临床I期子宫内膜样或浆液性子宫内膜癌患者1044例。
- 其中子宫内膜样癌959例,浆液性癌85例。
主要发现
- 510例无浸润FIGO 1/2级子宫内膜样癌患者中无SLN阳性,ITC发生率<1%。
- 1级内膜样癌内半肌层浸润SLN阳性率4.5%(9/202),外半为10%(6/62);2级分别为4%(3/76)和20%(8/41)。
- 3级内膜样癌无浸润、内半和外半肌层浸润的SLN阳性率分别为5%(1/20)、3%(1/31)和24%(4/17)。
- 深肌层浸润的1/2级肿瘤中ITC发生率为25%,深肌层浸润的3级肿瘤为18%。
- 41例无浸润浆液性癌中4例(10%)存在ITC或SLN阳性;隐匿卵巢转移在1/2级中为0,3级为2/68(3%),浆液性癌为2/85(2%)。
临床怎么用
- 对于低级别无肌层浸润子宫内膜样癌,可考虑省略SLN超分期。
- 对于无浸润浆液性癌,应进行SLN超分期以检测ITC或微转移。
- 高危组织学类型患者应评估隐匿卵巢转移可能。
局限性
- 回顾性研究设计。
- ITC的临床意义尚未明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We report the incidence of occult nodal metastasis in patients who underwent primary surgical staging for apparent early endometrioid or serous endometrial cancer with bilateral SLN mapping and enhanced pathology. Occult ovarian metastasis rates were also reported. METHODS: Patients with clinical stage I serous or endometrioid endometrial cancer who underwent primary staging surgery with successful bilateral SLN mapping from 1/2005-12/2018 were retrospectively evaluated. Rates of isolated tumor cells (ITCs), micro- and macrometastatic nodal disease, and occult ovarian involvement were reported. RESULTS: Of 1044 patients, 959 had endometrioid and 85 serous carcinoma. There were no positive SLNs among 510 patients with noninvasive FIGO grade 1/2 endometrioid carcinoma and < 1%ITCs. Grade 1: 4.5%(9/202) with inner-half and 10%(6/62) with outer-half myoinvasion had positive SLNs. Grade 2: rates were 4%(3/76) and 20%(8/41), respectively. Grade 3: 5%(1/20) with noninvasive, 3%(1/31) with inner-half, and 24%(4/17) with outer-half myoinvasion had positive SLNs. ITC incidence increased with depth of myoinvasion-25% of deeply invasive grade 1/2 and 18% of deeply invasive grade 3 tumors. Four (10%) of 41 patients with noninvasive serous endometrial carcinoma had ITCs or positive SLNs. There were no occult ovarian metastases with grades 1/2 disease, 2/68 (3%) with grade 3 disease, and 2/85 (2%) with serous endometrial carcinoma. CONCLUSION: Ultrastaging SLNs may be unwarranted in low-grade noninvasive endometrioid cancer but valuable in noninvasive serous carcinoma. Occult ovarian metastasis is uncommon in early endometrial carcinoma and occurs in 2-3% of high-risk histologies. Further research is needed to determine ITC significance, particularly with regard to adjuvant treatment.
引用
- Mueller JJ, Pedra Nobre S, Braxton K, et al. Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma. Gynecol Oncol. 2020. PMID: 32247604. doi:10.1016/j.ygyno.2020.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。